In this case-based activity, Pamela Ryan, RN, BSN from Ochsner Medical Center and Donna Williams, RN from Stanford Medicine discuss signs and symptoms of carcinoid syndrome in patients with NETs and the application of supportive care strategies to provide symptom relief.
This activity features an expert-led, case-based discussion with Thomas A. Abrams, MD from Dana-Farber Cancer Institute and Harvard Medical School on evolving antiangiogenic strategies with multikinase inhibitors in first- and second-line treatment of advanced HCC.
Watch this CME/CE-certified discussion with Tanya Dorff, MD from the Keck School of Medicine as she discusses progress in our understanding of predictive/prognostic markers in advanced prostate cancer as well as optimizing treatment sequencing and response assessment.
In this case-based activity, leading clinical investigator Jochen Lorch, MD, MS from Dana-Farber Cancer Institute will share insights into evidence-based personalized care planning for patients with differentiated and medullary thyroid cancer.
In this case-based activity, leading clinical investigator Oliver Sartor, MD examines recent developments and best practices in treatment selection and supportive care planning for patients with metastatic CRPC.
VTE is a common and potentially life-threatening complication in patients with cancer. This online activity reviews venous thromboembolism pathophysiology, risk assessment, and supportive care interventions for ambulatory cancer patients.
This live activity will bring a leading clinical investigator to your VA/DoD medical center to discuss emerging data on treatment selection, resistance, and response in CRPC. Schedule a meeting at your institution today!
This live activity will bring a leading clinical investigator to your cancer center to discuss emerging data in treatment selection and supportive care for patients with previously untreated and relapsed/refractory FL. Enroll your institution today!
This activity will bring a leading clinical investigator to your cancer center to discuss emerging data on PARP inhibitors that can rationally inform the management of ovarian cancer. Enroll your institution today!